What Goes Into Making Our Seasonal Flu Jab? – Expert Q+A
As most seasonal influenza vaccines are made using chicken eggs, the SMC asked experts for background on seasonal flu vaccine manufacture and alternatives to the standard jab.
How are the eggs to make traditional seasonal flu vaccines procured and kept safe from other pathogens, like avian influenza? Why do seasonal flu vaccines work better some years than others? And what other kinds of flu jabs are there?
Most seasonal influenza vaccines are made using chicken eggs.
The SMC asked experts for background on seasonal flu vaccine manufacture and alternatives to the standard jab.
Dr Mary Nowlan, Senior Advisor, Immunisation Advisory Centre (IMAC), comments:
Where do the eggs come from to make the seasonal influenza vaccine?
'Egg-based influenza vaccine manufacture is a well-established process, with chicken eggs being the preferred medium to grow viruses since the 1950s.
'Large quantities of eggs are produced in specific pathogen-free chicken colonies. These are controlled environments in which the hens and the eggs are closely monitored, which means that every step is taken to ensure that these animals are not at risk of being infected by bird influenza strains (including H5N1).'
Why do influenza vaccines work better some years than others?
'Predicting and matching exact influenza strains is an imperfect science, and vaccines that are developed are not always a perfect match for the circulating virus.
'Growing enough virus for millions of doses of vaccine is a slow process, particularly in eggs. As the virus grows in eggs, small changes occur in the virus – known as 'egg-adaption'. This can mean that the virus produced does not completely match the circulating virus, thereby potentially reducing the effectiveness of the vaccine.
'Another reason that the vaccine effectiveness can alter each year is that the wild virus strains have also mutated over the six months since they were selected for the vaccine and a mismatch can also occur. Advances in technology to analyse the circulating strains may have mitigated that risk to some degree, but the unpredictability of influenza virus evolution means mismatches still occur.'
How is it decided which strains are covered by the flu vaccines for the upcoming flu season?
'As the influenza virus continually mutates, vaccine production must take this into account and adjust the virus strains for the following influenza season.
'The Global Influenza Surveillance and Response System collates data from the WHO Collaborating Centres, who in turn receive data from the National Influenza Centres (ESR in New Zealand).
'This provides data for both the Southern and the Northern Hemispheres to help to predict which influenza strains are likely to circulate during their respective flu seasons each year.
'At around six months before the next influenza season, the WHO holds a meeting (in October and April – one for each hemisphere) to decide on the composition of upcoming influenza virus vaccines. Once this has happened, production of the next year's vaccine begins.
'The reason that influenza vaccine is recommended annually is due the constant changes in the influenza virus strains, and therefore the vaccine needs to alter in response. Protection only lasts for a short time.'
What are the alternatives to the standard flu vaccine?
'All the current seasonal influenza vaccines rely on recommendation from the WHO as to which influenza strains are included. Vaccines available in New Zealand include a cell-based vaccine, in which the virus is grown in cell culture rather than eggs, and an 'adjuvanted' vaccine, in which a naturally occurring compound (squalene) is added to induce a stronger immune response in older people who may have a weaker immune response than young adults.
'Further vaccines available internationally but not New Zealand include recombinant influenza vaccines, in which the surface proteins of the virus are produced artificially rather than being isolated from whole viruses. Also available in the Northern Hemisphere is a live attenuated influenza vaccine that is given through a nasal spray, usually to children.'
Why should we be concerned about bird flu in New Zealand?
'Birds, particularly wading birds, carry influenza virus in their guts. Usually this does not make the birds sick. However, some forms of avian flu have become deadly. Highly pathogenic avian influenza (HPAI) is of significant concern, not only for the risk of spread to humans but for wild and domestic birds and other animals such as livestock. H5N1 is just one strain of avian influenza that can mutate to make animals sick. It has also infected humans who were exposed to sick animals.
'As well as concerns about infection in birds, livestock, and marine mammals in New Zealand, a big concern in humans would be if a HPAI infected someone who is also infected with the seasonal influenza virus. The risk is that the influenza viruses would combine into a strain that is transmissible between humans. This has the potential to cause a pandemic. People who work with animals are encouraged to receive the seasonal influenza vaccine each year to reduce this risk.'
No conflicts declared.
Dr Lisa Connor, Programme Leader, Infection and Vaccinology Group, Malaghan Institute of Medical Research, comments:
Could the ongoing impact of the H5N1 avian flu pandemic on raised chickens overseas have flow-on effects on influenza vaccine availability in NZ?
'One widely used influenza vaccine in New Zealand is the Tetra Fluvac, which provides protection against four different flu virus variants. This vaccine is produced using eggs and is available for free to eligible New Zealanders, making it an accessible and effective option.
'However, it is important to note that there are also other flu vaccines available on the market that do not rely on egg-based production. These vaccines are made using cell cultures and, while not currently funded by the NZ government, they are an alternative for those who require or prefer them. These non-egg-based vaccines are available in New Zealand but are typically more expensive, as they are not covered by the public funding system.
'H5N1, the avian influenza strain, is a significant concern, especially for our bird population, including chickens. Thus, there is the potential to disrupt egg production and, consequently, vaccine production. Fortunately, the availability of cell culture-based vaccines ensures that there are safe, effective, and approved alternatives on the market that do not depend on eggs. This flexibility is reassuring, as it means that if egg production were to be impacted by H5N1 or other factors, we have viable options to ensure continued vaccine supply.
'Overall, the current flu vaccines, including the egg-based Tetra Fluvac can lower the risk of infection and reduce severity of disease from influenza, and many New Zealanders are eligible for free vaccination. Should the situation evolve and potential shortages arise, the availability of mammalian cell culture-based vaccines offers a solid backup. We are fortunate that there are multiple, effective vaccine options in New Zealand, ensuring that the public remains well-prepared to limit infection from influenza, regardless of future challenges.'
No conflicts of interest.
Natalie Netzler PhD, Senior Lecturer, Faculty of Medical and Health Sciences, University of Auckland, comments:
'The current egg-based vaccines are produced in a manufacturing system that is over 70 years old. However, there is a lengthy lead time needed to secure the eggs required to make the egg-based flu vaccine.
'Following the 2009 influenza pandemic we had a shortage of egg-based vaccines due to a number of issues including slow virus growth of the pandemic strain in eggs and a very high demand coupled with the slow manufacturing process.
'Given that our Indigenous populations all over the world face higher rates of severe influenza compared to non-indigenous groups in the same regions, it is important that we have sufficient vaccine supplies to protect our unique Māori and Pacific communities here in Aotearoa NZ.
'The development of cell-based influenza vaccines is gaining traction. While there are some challenges posed by these newer flu vaccines including higher costs of production, and limited global availability, there are several advantages of cell-based vaccines over egg-based flu shots. These include faster and more predictable rates of production and being able to offer an egg-free option.
'Although our current influenza vaccines are not perfect in that they don't always stop you getting the flu altogether, they do offer protection against severe flu and are highly recommended for those at risk of severe disease, no matter which type of flu vaccine you get.'
Conflict of interest statement: 'I work with several Pacific and Māori organisations and health providers to support our communities to make informed decisions on immunisation.'
Sue Huang, Director, WHO National Influenza Centre, Institute of Environmental Science and Research (ESR), comments:
What strains are covered in this year's flu vaccines?
'The southern hemisphere influenza vaccines to be used in NZ in 2025:
Egg-based vaccines:
• an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
• an A/Croatia/10136RV/2023 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell culture-, recombinant protein- or nucleic acid-based vaccines
• an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
• an A/District of Columbia/27/2023 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
'Interestingly, the influenza vaccine strains recommended by WHO in February 2025 for the use for northern hemisphere countries in 2025-2026 are the same as the NZ's vaccine strains to be used in 2025. This suggests that our vaccine strains match well with the current circulating viruses which would give us optimal protection. Influenza vaccination is the primary tool to protection us against influenza, particularly for those vulnerable groups (elderly, and individuals with underlying conditions).
'At the moment, influenza activity is still at a low level. Influenza A(H1N1)pdm09 is the predominant strain followed by influenza B and A(H3N2). For details, see here.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
3 hours ago
- RNZ News
Over 31 cases of polio in Papua New Guinea
Photo: The World Health Organisation In Papua New Guinea, more than 31 cases of polio have been detected since the disease re-emerged earlier this year. The World Health Organisation (WHO) confirmed the numbers on Monday, as PNG launched a national immunisation campaign in Port Moresby. The WHO declared an outbreak in May after two children were confirmed to have the virus. Polio or poliomyelitis is a highly infectious disease that mainly affects children under five. It can also affect older age groups. Most people who have it have no symptoms, but it can lead to irreversible paralysis in about one in 200 infections, or one percent of cases. The virus is spread by person-to-person contact or the ingestion of contaminated virus from faeces. Because the virus multiplies in the gut of infected people, who then shed it in their stool for several weeks, it can spread through a community, particularly in areas with poor sanitation. The WHO said over 31 detections of the virus had been confirmed in Papua New Guinea through environmental and community surveillance since May. While no cases of paralysis had been reported, the risk of further transmission remained high due to low immunisation rates and poor access to children who lived in remote areas. The WHO said the vaccine campaign would focus on the mainland provinces, of which 17 had been identified as high-risk areas. Here, both the oral polio vaccine and the polio vaccine jab were due to be administered. The New Guinea Islands provinces had been deemed lower-risk, and one round of the polio vaccine injection had been planned. "This moment represents more than just a public health initiative - it is a bold step forward in our shared mission to secure the health and future of Papua New Guinea's youngest generation," WHO Papua New Guinea representative Dr Masahiro Zakoji said. Last year, UNICEF highlighted Papua New Guinea's low childhood immunisation coverage. It found only about 50 percent of children born each year received "essential life-saving vaccines", which included the oral polio vaccine. That left about 120,000 children unvaccinated each year, the agency said. It said to prevent outbreaks and reach herd immunity against polio, vaccine coverage should be at least 95 percent. The agency said that while the global prevalence of the disease had plummeted by more than 99 percent in the past 35 years, millions of children were still affected because they missed out on the vaccine. Most of these children (85 percent) were living in "fragile settings", UNICEF said. These included countries and communities where there was conflict, natural disasters and humanitarian crises. In 2000, Papua New Guinea had been declared polio-free, but 18 years later, an outbreak of vaccine-derived polio type 1 was declared. It resulted in 26 cases across nine provinces in 2018. The US Centre for Disease Control and Prevention (CDC) said this strain is related to the weakened live polio virus used in oral polio vaccine. If allowed to circulate in populations which have low immunisation rates or are unimmunised "for long enough", or replicate in "an immunodeficient individual", the weakened virus can revert to a form that causes illness and paralysis, the CDC said. The WHO said the 2018 Papua New Guinea outbreak was brought under control through further rounds of vaccination, community engagement and better surveillance of the disease. Meanwhile, the current outbreak is related to vaccine-derived poliovirus type 2. In May, Papua New Guinea's health department said the strain was a "rare form of the virus that can emerge in under-immunised communities but is well understood and can be effectively controlled through vaccination".
RNZ News
4 days ago
- RNZ News
Nearly 12,000 children under five in Gaza have acute malnutrition, says WHO
By Olivia Le Poidevin , Reuters A Palestinian woman holds a severely malnourished baby, amid a deepening humanitarian crisis in the territory. Photo: ABOOD ABUSALAMA / Middle East Images via AFP Around 12,000 children aged under five in Gaza are suffering from acute malnutrition, and hunger-related deaths are rising , the Director General of the World Health Organization says. "In July, nearly 12,000 children under five years were identified as having acute malnutrition in Gaza, the highest monthly figure ever recorded," Tedros Adhanom Ghebreyesus said at his organisation's headquarters in Geneva. At least 99 people have died, including 64 adults and 35 children, of whom 29 were younger than five, from the start of this year to July 29. Between June and July, the number of admissions for malnutrition almost doubled - from 6344 to 11,877 - according to the latest UNICEF figures available. Some 2500 of those children are suffering from severe malnutrition. Tedros called for greater volumes of sustained aid, via all possible routes. The WHO said it was supporting Gaza's four malnutrition centres, but that supplies of baby formula and nutritional foods were very low. "The overall volume of nutrition supplies remains completely insufficient to prevent further deterioration. The market needs to be flooded. There needs to be dietary diversity," said Rik Peeperkorn, WHO's representative for the occupied Palestinian Territory, via video link. A global hunger monitor has said a famine scenario is unfolding in the Gaza Strip, with starvation spreading, children dying of hunger-related causes and humanitarian access to the embattled enclave severely restricted. The United Nations Office for the Coordination of Humanitarian Affairs said food consumption across Gaza had declined to its lowest level since the onset of the war. Eighty-one percent of households in the tiny, crowded coastal territory of 2.2 million people reported poor food consumption, up from 33 percent in April. - Reuters
Scoop
5 days ago
- Scoop
Defunding Of mRNA Vaccine Research In The US
This week, the US Health Department announced the cancellation of several mRNA vaccine development contracts. The cuts and restructuring of collaborations affect 22 projects worth about half a billion US dollars, and no new mRNA projects will be funded. The US Secretary of Health, Robert F. Kennedy, Jr., claimed mRNA vaccines don't provide effective protection against upper respiratory tract infections and said that funding would be shifted towards 'safer, broader vaccine platforms'. The SMC asked experts to comment on how this affects NZ and local mRNA vaccine research. Professor Kjesten Wiig, Co-director of the RNA Development Platform and Director of the Malaghan Institute of Medical Research, comments: 'The recent decisions out of the US to cut funding for mRNA vaccine development represent a new low for the American medical and scientific community, one that risks undermining decades of progress in public health and infectious disease preparedness. 'At the Malaghan Institute, our research is not directly affected by US funding cuts. Likewise, the national RNA Development Platform continues to receive sustained support from the New Zealand Government. This backing allows us to focus on developing safe and effective RNA vaccines and therapeutics not just for human medicine but also for treatments that will benefit our primary industries, and for New Zealand specific problems. 'RNA is a proven, safe and transformative technology. Its potential extends well beyond the pandemic. In the absence of US leadership, there is an unprecedented opportunity for countries like New Zealand to step up to ensure this breakthrough science continues to benefit people globally.' No conflicts of interest. Our colleagues at the UK SMC have also gathered comments. A small selection follows—see their website for the full expert reaction. Prof Christopher Chiu, Professor of Infectious Diseases, Imperial College London, said: 'Hundreds millions of people received mRNA vaccines during the pandemic with no major ill effects, dramatically reducing the risk of severe COVID-19, hospitalisation and death. In this way, they played a critically important part in allowing society to return to normal. Overall, the mRNA vaccines have been shown to be very safe, although like all treatments they can cause side effects, mostly mild but including some rare severe reactions. It is misleading to single out mRNA vaccines for promoting mutations and failing to protect against common cold-like symptoms; this is true for all respiratory virus vaccines that are given by injection and can stimulate a protective immune response. Better protection is needed but until we have next-generation alternatives that can completely block infection in the nose and lung, mRNA vaccines will continue to be important and valuable.' No conflicts of interest. Dr David Elliman, Honorary Associate Professor, UCL, said: 'This is a very worrying development. mRNA vaccines were an extremely important tool in saving the lives of people from COVID. There is no reliable published evidence that supports RFK Jr's assertion that the vaccines encourage new mutations and, in so doing, may prolong pandemics. The evidence to support this should be made public, so that it can be examined, by experts in the field who have not been picked because of their anti-vaccine views. 'While this development is not only a retrograde step for the development of mRNA vaccines, of greater concern, perhaps, is that it reinforces the impression that, in spite of his protestations, RFK Jr is antivaccine. This has implications, not only for vaccination programmes in USA, but around the world. At a time when vaccination rates are falling globally, we need to follow the evidence, not ideologically led beliefs. Such misguided beliefs are likely to cause unnecessary suffering and death, particularly in children.' No conflicts of interest. Prof Robin Shattock, Professor of Mucosal Infection and Immunity, Imperial College London, said: What do we know about the safety and efficacy of mRNA vaccines? 'Following their use in millions of individuals during the pandemic and using current technology, we have an extraordinary level of detail on the safety and efficacy of mRNA vaccines. In the context of COVID-19, these vaccines prevented millions of deaths and hospitalisations. As for mRNA vaccines against other infectious these would need to be evaluated on a case-by-case basis. Do mRNA vaccines increase the mutation rate of viruses? 'No, there is no scientific evidence that this is the case. Different viruses mutate at different rates, for example influenza virus changes on a seasonal basis, SARS-CoV2 continues to vary irrespective of whether individuals have received mRNA vaccines. What are the impacts of this funding cut on public health and health research in the US and globally? 'This will impoverish American resilience to future pandemics. But more importantly, it will be used by some to legitimise unfounded claims that mRNA vaccines and vaccines in general are unsafe. This is directly opposite to the scientific evidence-based approach to science. This technology offers real benefits not only against infectious diseases, but also in our fight against cancer, autoimmunity, and hereditary diseases. If known, what data might he [R.F. Kennedy Jr] be referring to and how does it compare with other existing evidence? 'It is unclear as to what evidence he is referring to, given that these vaccines have been highly scrutinised by regulatory bodies on an ongoing basis (FDA, EMEA, MHRA). He has provided no evidence to show that alternative vaccines are any different to mRNA vaccines concerning claims of safety and the unfounded claim that mRNA vaccines drive the mutation rate of viruses. Any other considerations you have about the claims being made? 'This is another blow against vaccine uptake in general, where for example, we are seeing the return of Measles outbreaks in the US and unnecessary deaths.' Conflict of interest statement: 'I work on RNA vaccines in an academic setting, but have no associations with any of the work that is being axed by RFK or the companies involved.'
